Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.
Journal article
Reinke S. et al, (2023), Cell rep med, 4
Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions.
Journal article
Mukhopadhyay E. et al, (2022), Biotechnol bioeng
Virus-like particle vaccines
Chapter
Mukhopadhyay E. et al, (2022), Vaccinology and Methods in Vaccine Research, 163 - 176
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Journal article
Datoo MS. et al, (2021), Lancet, 397, 1809 - 1818
Efficacy of a low dose candidate malaria vaccine, R21 in adjuvant Matrix-M™, with seasonal administration to children in Burkina Faso
Journal article
EWER K. et al, (2021), The lancet
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article
Barrett JR. et al, (2021), Nat med, 27, 279 - 288
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Journal article
Voysey M. et al, (2021), Lancet, 397, 99 - 111
Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites.
Journal article
Kolli SK. et al, (2021), Plos one, 16
SAFETY, IMMUNOGENICITY AND DURABILITY OF A NOVEL MALARIA VACCINE CANDIDATE, R21 ADJUVANTED WITH AS01(B)
Conference paper
Venkatraman N. et al, (2017), American journal of tropical medicine and hygiene, 97, 132 - 132
SAFETY AND IMMUNOGENICITY OF WITH NOVEL MALARIA VACCINE CANDIDATE, R21 ADJUVANTED WITH MATRIX M1
Other
Venkatraman N. et al, (2017), American journal of tropical medicine and hygiene, 95, 123 - 123